Vulcan Biologics Inc.
- UEI
- LNBVDMU2KNN5
- CAGE
- 8FEM6
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- vulcanbiologics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $299,914 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir topic 131 - new award to vulcan biologics | National Institute of Allergy and Infectious Diseases (NIH) | $299,914 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Intralytix Inc. | Columbia, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Locus Biosciences Inc. | Morrisville, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Phagepro, P.b.c. | Somerville, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Topaz Biosciences, Inc. | Emeryville, CA | — |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Vulcan Biologics Inc. is a corporate entity registered in SAM.gov, specializing in microbiome engineering and bacteriophage-based technologies. Located in Irvine, California, the company is a self-certified small disadvantaged business focused on developing innovative solutions in microbial gene therapy and microbiome modulation. Their core technological approach involves using bacteriophages to deliver targeted genetic modifications within complex microbial communities, with potential applications in environmental remediation, agriculture, and human health.
In terms of federal contract awards, Vulcan Biologics Inc. has received a notable SBIR Phase I contract from the National Institute of Allergy and Infectious Diseases (NIAID), valued at $299,914. This contract, set aside for small businesses, focuses on developing bacteriophage treatments for mycobacterial infections. The contract is a firm fixed-price award and supports innovative research aligned with NIH and CDC mission needs. The project is designated under the SBIR Topic 131 program and is scheduled for completion by September 9, 2025, representing the company's initial foray into federal contract work targeting infectious disease solutions.
Regarding federal grant awards, Vulcan Biologics Inc. has secured multiple grants from agencies like the National Science Foundation and National Institutes of Health. The most significant grant is a $989,854 cooperative agreement from the National Science Foundation's Division of Industrial Innovation, supporting the development of a bacteriophage-based microbial gene therapy platform for in situ microbiome engineering. Additionally, they received a $267,556 grant from the National Institute of Dental and Craniofacial Research to develop an innovative approach for modulating the supragingival microbiome to prevent dental caries. These grants, predominantly through SBIR Phase I and Phase II programs, demonstrate the company's commitment to advancing microbiome-related technologies across various research domains, including oral health, microbial engineering, and disease treatment.
Quick answers
Is Vulcan Biologics Inc. registered in SAM.gov?
Vulcan Biologics Inc.'s SAM.gov registration expired on March 8, 2026.
How much has Vulcan Biologics Inc. received in federal contracts?
Federal contracts obligated $299,914 to Vulcan Biologics Inc. in fiscal years 2023 through 2027.
What is Vulcan Biologics Inc.'s most recent federal award?
Vulcan Biologics Inc.'s most recent federal contract award is Sbir topic 131 - new award to vulcan biologics (75N93024C00061), from National Institute of Allergy and Infectious Diseases (NIH), on September 10, 2024.
On GovTribe
See Vulcan Biologics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors